Is Addex Therapeutics Ltd (ADXN) a Buy, Sell, or Hold?
NASDAQ : ADXN
Addex Therapeutics Ltd — News
$5.95 USD
$0.15 (2.59%)
- Volume
- 2.1K
- Average Volume
- 2.92K
- Market Capitalization
- $7.33M
- P/E Ratio
- -0.71
- Dividend Yield
- 0.00%
- Price Target
- $30.00
- Year High
- $12.05
- Year Low
- $5.04
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.97
| Source | Headline |
|---|---|
|
Addex Therapeutics Ltd (ADXN) Q1 2026 Earnings Call Transcript
Addex Therapeutics Ltd (ADXN) Q1 2026 Earnings Call Transcript seekingalpha.com - 2026-06-25 13:12:13 |
|
Addex Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 25, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its Q1 2026 financial results and provided a corporate update. globenewswire.com - 2026-06-25 01:00:00 |
|
Addex Therapeutics to Report 2026 First Quarter Financial Results and Host Conference Call on June 25, 2026
Geneva, Switzerland, June 22, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will report its First Quarter 2026 Financial Results on June 25, 2026. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science, will provide a business update and review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) on June 25, 2026. globenewswire.com - 2026-06-22 01:00:00 |
|
Addex Convenes Annual General Meeting 2026
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 5, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that its 2026 Annual General Meeting will take place on Monday June 29, 2026 at 11:00 am CEST at the Campus Biotech, Chemin des Mines 9, 1202 Geneva (doors open at 10:30 am). globenewswire.com - 2026-06-05 01:00:00 |
